CP-870893 0.2 mg/kg (Escalation Cohort) [clinicaltrials_resource:NCT00711191/group/B2]
Participants received chemotherapy (gemcitabine) with a starting dose of 1000 mg/m^2 IV on Day 1, 8, and 15 of every 28 day cycle up to a maximum of 12 cycles. If 0 out of 3 or <2 out of 6 participants in the CP-870893 0.1 mg/kg cohort experienced a dose limiting toxicity in Cycle 1, subsequent participants were enrolled in the 0.2 mg/kg dose cohort and received CP-870893 0.2 mg/kg IV on Day 3 of every 28 day cycle (0.2 mg/kg escalation cohort) for up to a maximum of 12 cycles.
group [clinicaltrials_vocabulary:group]
NCT00711191 measurement [clinicaltrials_resource:NCT00711191/measurement/0b9522e31e21cf1620a2b1fffb29f67a]NCT00711191 measurement [clinicaltrials_resource:NCT00711191/measurement/2230638dce05d4bc1715073eb74419f3]NCT00711191 measurement [clinicaltrials_resource:NCT00711191/measurement/279f56328c5a5a6a240a757e662f2abf]
group id [clinicaltrials_vocabulary:group-id]
CP-870893 0.2 mg/kg (Escalation Cohort) [clinicaltrials_resource:NCT00711191/group/B2]
Participants received chemotherapy (gemcitabine) with a starting dose of 1000 mg/m^2 IV on Day 1, 8, and 15 of every 28 day cycle up to a maximum of 12 cycles. If 0 out of 3 or <2 out of 6 participants in the CP-870893 0.1 mg/kg cohort experienced a dose limiting toxicity in Cycle 1, subsequent participants were enrolled in the 0.2 mg/kg dose cohort and received CP-870893 0.2 mg/kg IV on Day 3 of every 28 day cycle (0.2 mg/kg escalation cohort) for up to a maximum of 12 cycles.
Bio2RDF identifier
NCT00711191/group/B2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00711191/group/B2
group id [clinicaltrials_vocabulary:group-id]
description
Participants received chemothe ...... up to a maximum of 12 cycles.
@en
identifier
clinicaltrials_resource:NCT00711191/group/B2
title
CP-870893 0.2 mg/kg (Escalation Cohort)
@en
type
label
CP-870893 0.2 mg/kg (Escalation Cohort) [clinicaltrials_resource:NCT00711191/group/B2]
@en